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 Abstract 
Molecular Analysis of Oligoclonal T cells Associated with Graft-Versus-Host Disease 
Following Allogeneic Stem-cell Transplantation 
 
By Kassi M. Avent 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Master’s of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
Director: Masoud Manjili, DVM, PhD 
Professor of Microbiology and Immunology 
 
The goal of hematopoietic stem cell transplantation (HSCT) is to induce graft-versus-tumor 
effect (GVT), which is the recognition of and response against tumor- associated antigens (TAAs) by 
donor immune cells to clear the recipient of residual tumor.  A complication of HSCT as a treatment 
for hematologic malignancies is graft-versus-host disease (GVHD), which is the recognition and 
reactivity of donor immune cells against healthy tissues. As of now, the differentiation between 
GVHD and GVT effects has been a hindrance to the development of effective therapies against 
GVHD. Certain T cell clones may induce both GVHD and GVT effects, making targeted therapy of 
GVHD difficult. This project was aimed to uncover differences at a molecular level of the T cell 
recognition site that exist between patients with GVHD and those with GVHD-free survival 
following allogeneic HSCT. We found that there are inherent differences in the T cell receptor at a 
molecular level between patients experiencing GVHD and those that are GVHD-free, suggesting the 
ability of T cells to distinguish tumor cells from self cells. In addition, the intention was to reveal 
differences in proportions of engrafted donor T cells and stem cells and the effects of these 
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proportions on the severity, outcome, and prognosis of GVHD. We additionally found that a lower 
proportion of stem cells to T cells was associated with the trend of GVHD, while a higher frequency 
of T cells engrafted into host may indicate resistance to treatment and a poor prognosis.  These data 
suggest that allogeneic HSCT may be improved by optimizing the proportion of T cells to stem cells 
in the transplant as well as developing targeted therapy against GVHD-associated T cell clones while 
rescuing GVT-associated T cell clones. 
 
 
 
Introduction 
 
Hematopoietic Stem Cell Transplantation 
 
Hematopoietic stem cell transplantation (HSCT) is used in the treatment of hematological 
disorders as a curative therapy and works by the intravenous infusion of healthy donor cells in order to 
replace diseased host hematopoietic cells following their T cell depletion.1 An added benefit of the use 
of HSCT in the treatment of blood cancer patients is graft- versus- tumor effect (GVT), which is the 
involvement of donor T cell recognition of tumor antigen in the immune response against blood cancer. 
However, the success of HSCT is limited by the onset of graft-versus-host disease (GVHD).  
 
Graft-versus-host Disease 
 
Graft- versus- host disease in this study is the result of donor T cells recognizing minor 
histocompatibility antigens (mHAs) presented by human leukocyte antigens (HLA) on host tissue and 
mounting a destructive response against them.2,3 It can be lethal, and is therefore of paramount concern 
when considering HSCT as a treatment option.4 Recognition of host cells by donor’s T cells is HLA-
dependant, which occur when a T cell recognizes and mounts an immune response to a foreign HLA 
molecule or nonself mHA presented by a self HLA molecule.3,5 Donors and recipients must be matched 
in HLAs in order to reduce the risk of GVHD. Therefore, HSCT is ideally conducted with donors that 
match recipients in at least five major HLAs (1 paternal and 1 maternal allele for each of the five HLAs 
matched), and allogeneic GVHD reaction must be beyond HLA mismatch. 3,6 This means that the 
recognition of host HLA by donor T cells is an unlikely method of GVHD induction. Antigenic peptides 
presented in the context of HLA, i.e. mHAs, on the other hand, are polymorphic protein products that 
may mismatch between HLA- matched donor and recipients, resulting in alloreactivity upon 
transplantation.2,7 Some mHAs are ubiquitously expressed on all tissue, whereas others are expressed 
primarily on hematopoietic cells.3 Antigens that are expressed ubiquitously are prime targets for GVHD, 
whereas those that are restricted to the hematopoietic system are more likely to function in GVT. 3,6 In 
addition, mHAs that are encoded by the Y chromosome (H-Y antigens) may result in GVHD or GVT 
reactivity in male recipients of female stem cells.5 The importance of mHAs is emphasized when 
considering that tumor cells are constantly undergoing immunoediting to rid themselves of highly 
immunogenic tumor associated antigens (TAA’s).8 The significance of mHAs is demonstrated in the 
observation that patients with HLA-matched unrelated donors are still more likely to develop GVHD 
than patients with HLA-matched related donors.4  
The conditioning regimen for preparation of HSCT in the host involves the use of a T cell- 
specific antibody (Thymoglobulin® {ATG}, in this particular study) that specifically targets the 
thymocytes of the recipient and initiates their destruction.6 This results in the removal of host T- cells 
from circulation, as ATG targets multiple markers specific to T cells.6 This treatment is designed to 
remove diseased host cells while allowing room within the host microenvironment for the growth and 
proliferation of donor cells, but also prevents recipient cells from mounting a counterattack against the 
donor cells once they have responded to healthy recipient tissue. This is designed so that recipient cells 
cannot cause rejection of the transplant.1,4,6   
GVHD occurs due to a combination of factors unique to the transplant setting. Primarily, the 
recipient is immunocompromised due to myoablative (via radiation) and/or lymphoablative (via 
chemotherapy and/or antibodies directed at lymphocytes) conditioning prior to donor cell introduction, 
in combination with the introduction of immunocompetent immune cells from donor that the host is 
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unable to reject.9 Since antigens recognized by donor immune cells may not be specific to tumor alone, 
GVT in many cases occurs in conjunction with GVHD.8 However, hematolymphoid cells are most 
susceptible to alloreactive T cells, thus, expression of tumor-specific antigens or tissue-restricted 
antigens on malignant cells may cause GVT reactivity without the co-occurrence of GVHD.8 It is 
therefore imperative to distinguish the minute, yet key differences in the recognition regions of immune 
cells that can allow for the differentiation of tumor versus healthy host tissue. Previous studies both in 
our lab and elsewhere have uncovered key Vβ families associated with both GVHD and GVT utilizing 
q-RT PCR, but so far a molecular exploration of amino acid sequences of the antigen-recognition site of 
the T cell receptor (TCR) have been insufficient. 10,11,12 
 
 
The T cell Receptor 
T cells are part of the adaptive immune response that play a major role in GVHD. In GVHD, T 
cells rely on differences in mHAs between donor and recipient that are matched in five major HLAs. 
This is demonstrated by the abolishment of both GVHD and GVT effects when T cells are depleted 
from the transplant or the donor is an identical twin.8 Host antigens such as mHA are presented to donor 
T cells in the context of HLA by host antigen-presenting cells (APC’s) that induce donor-derived T cell 
proliferation and differentiation during GVHD or GVT effects. 7,13 
 The T cell receptor (TCR) is a heterodimer made up of two chains, an alpha (α) and a beta (β) 
chain, linked by a disulfide bond and each with both a variable and a constant region. 5,14 The constant 
region links the TCR to the T cell via a positively charged transmembrane region.5 The variable region 
of the α chain contains a variable (V) and a junctional (J) gene segment and the variable region of the β 
chain also contains both the V and the J genes, with the addition of a diversity (D) gene segment in 
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between the two.5,14 These are the gene segments that rearrange to form the full TCR variable domain. 
The variable regions of the α and β chains align to form the antigen- recognition and binding site, and 
each TCR has one binding site. The TCR recognizes antigen bound to a major histocompatibility 
complex (MHC) molecule presented to it by an APC.5 The MHC gene in humans encodes HLA, for 
human leukocyte antigen, and the TCR must recognize and bind both antigen and HLA in conjunction in 
order for activation of the T cell to occur (a phenomenon called MHC restriction). 3,5 There are over 200 
HLA genes on the human chromosome 6, which produce a multitude of genes, 40 of which encode 
leukocyte antigens. HLA’s are divided into groups that fall into a three classes.2 Class I and class II 
HLA’s are of importance to this study because they have the potential to induce an immune reaction if 
not matched between donor and host properly.3 From these two classes the five HLA’s that are matched 
between donor and recipient can be found. In HLA class I, HLA-A, HLA-B, and HLA-C and in HLA 
class II HLA-DRB1 and HLA-DQB1 are matched between donor and recipient in HSCT. These five 
HLAs are selected due to their high diversity amongst individuals, and therefore high potential for 
alloreactivity if not properly matched. The nomenclature of class II genes derives from letters 
designating information on the gene that it encodes. The first letter (D) designates the class, the second 
the family (M, O, P, Q, R), and the final letter, the HLA chain in which it belongs (α or β).2 Numbers 
preceding an asterisk following the HLA name indicate the gene and numbers following the asterisk 
indicate the individual allele of which a particular HLA belongs.2 For example, HLA-DQB1*0301 
belongs to HLA-D class II gene, is in the Q family on the beta chain, and is 0301 allelic variant of gene 
1.2 Class I HLA’s are expressed on the surface of almost all somatic cells of our body (with exception of 
enucleated cells like red blood cells) while class II HLA’s are present on the surface of hematopoietic 
antigen presenting cells. 2,3,5 This key difference in HLA location stems from the activity that each cell 
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needs to induce in the T cell that they are presenting to. Antigen presented on a class I gene signals to 
CD8+ T cells, while antigen presented on a class II gene signals to CD4+ T cells.2,5  
There are three hypervariable loops in both the α and β chains known as complementarity 
determining regions (CDR) that make up the variable region of the TCR. The first two, CDR1 and 
CDR2, are contained entirely within the V gene, whereas CDR3 is made up of the combinations of the 
V, D, and J genes. The CDR3 is responsible for the antigen-recognition portion of the T cell: HLA 
complex. This is the region in which most of the diversity of the TCR is concentrated due to the method 
in which the TCR is generated.5 While all three CDR’s allow for specificity of the peptide:MHC 
(pMHC) complex, it is the highly diverse CDR3 region that is responsible for antigen specificity.5,15 T 
cells can be distinguished by their unique CDR3 region, and it is for these reasons that this particular 
region is studied so extensively in immune profiling.15   
    
 TCR β chain rearrangement 
 
The β chain of the developing T cell undergoes a consecutive, stepwise rearrangement of its 
genome that ensures a high amount of diversity within the T cell repertoire. The Vβ gene is located on 
chromosome 7 and is organized with the 52 V segments (part of 30 Vβ gene families) preceding two 
clusters that each contains one D and multiple J segments.5,16 Alternative splicing of V genes in addition 
to genetic polymorphisms in the V, D, and J genes provides a greater diversity than the initial 30 V 
genes would confer in addition to the 2 D and 13 J genes. 5,16,17 An enzyme complex called 
recombination-activating genes (RAG)  that recognize signals (recombination signal sequences, RSS) at 
the ends of each region and join one V, D, and J end-on- end in a process called somatic 
recombination.5,14 These recombination signal sequences allow for very precise joining of each gene 
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segment.14 At the junction points (between V and D and between D and J), random nucleotide insertions 
and subtractions contribute diversity of CDR3 region, which is formed at the junction site of these 
genes. An enzyme called terminal deoxyncleotidyl transferase (TdT) is responsible for this process 
during the joining of each segment to another. The D and the J segments join one another first, followed 
by the joining of the DJ segment to the V segment, and the joining of the entire VDJ region to the 
constant region. 5 Following somatic recombination events, each complete Vβ exon will have one V, D, 
and J region.5,14 These genes rearrange during thymic development.5 This process generates diversity in 
a number of ways. Firstly, the number of different gene segments allows for a multitude of different 
potential combinations, leading to what is known as combinatorial diversity. A second type of 
combinatorial diversity is the result of the potential of various combinations of a variety of Vβ and Vα’s. 
Finally, junctional diversity arises from the addition and subtraction of nucleotides at junction sites as 
part of the recombination process.5 
Upon successful recombination of a complete β chain, signals to the T cell halt β chain 
rearrangement so that only one allele is expressed and all others are silenced (allelic exclusion).This 
works by the expression of a pre-T cell receptor, which induces the phosphorylation and subsequent 
degradation of RAG acting on the β chain.5 Successful rearrangement of the β chain also induces cell 
proliferation.5 After the cells have undergone numerous divisions, the α chain rearranges, leading to a 
single β chain being associated with a large number of different α chains. At this point of both the α and 
the β chains rearranged and expressed, positive and negative selection can begin.5 After a selected T cell 
has been released into the periphery, stimulation by contact with a pMHC complex induces mass 
proliferation of the particular T cell specific to the stimulating antigen. For this reason, a skewed 
depiction of a particular VJ recombination on a T cell is indicative of an antigen-specific response. 15,18 
The use of spectratyping to derive information on skewed clonality is imperative in uncovering VJ 
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recombinations that are upregulated during a disease state. The spectraype methodology works by 
displaying each of the V genes in correspondence with the 13 J genes that it can be paired with. An 
increase in one VJ recombination at the expense of the others within a V gene will be depicted as a peak 
in the graph. This skewed mono- or oligo-clonality is indicative of an antigen- specific response and in 
contrast to healthy individuals who have a diverse repertoire of VJ recombinations (polyclonality). 19  
 
Maturation and Proliferation of T cells 
 
Although T cell progenitors are derived from the bone marrow, T cell lymphopoiesis and 
maturation occur in the thymus. Multipotent hematopoietic progenitor cells migrate to the thymus via 
the blood where they then begin maturation into T lymphocytes. The thymus is the site for the genetic 
recombinations that give rise to the billions of different T cells capable of recognizing and responding to 
different epitopes (antigenic determinants).5 The thymus is also responsible for both positive and 
negative selection of T cells which leads to a large majority of T cells (96-98%) that are eliminated from 
the repertoire due to strong reactivity to self, or inability to recognize MHC. Thymic cell signaling is 
necessary for both parts of this selection. In positive selection, only those thymocytes (developing T 
cells) that bind to thymic MHC molecules, and therefore have the potential to recognize antigen being 
presented on them, are given the survival signal needed to continue on by those thymic cells. 
Thymocytes that do not bind MHC do not receive this survival signal and undergo “death by neglect”. 
5,20 In fact, MHC restriction is determined by positive selection. In negative selection, thymocytes that 
recognize host cells with high affinity for pMHC are given a signal to undergo apoptosis due to 
overstimulation. These two selective processes are critical in eliminating T cells that have the potential 
to recognize and attack host cells, and leads to central tolerance.5 In normal circumstances, the 
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presentation of a non-harmful stimulus in the periphery in the absence of co-stimulation (the “second 
signal”) that denotes a harmful antigen, the potentially reactive cell undergoes anergy, in order to induce 
peripheral tolerance.5 In the stem-cell transplant environment, inflammation from chemotherapy and/or 
pre-HSCT treatment regimens can induce expression of co-stimulatory molecules. This can lead to 
overcoming this peripheral tolerance process and the activation of T cells against potentially non-
harmful stimuli.5 
 The thymus begins to deteriorate with age, and the critical ability of selection of T cells gradually 
diminishes. Thymic activity peaks in infancy, and begins its gradual decline after one year of age.21,22  
After middle age, the thymus shrinks by about 1% annually.23 By the age of 60, thymic function is 
drastically reduced, and additionally loses its ability to rebound from damage.24,25,26 Thymic epithelium, 
which is critical for positive and negative selection of developing T cells, is gradually converted to 
adipose tissue.25 Thymic function still allows for the development of new T cells, albeit at a much 
slower rate as age progresses.25 All that being said, involution of the thymus produces no noticeable 
adverse affects in the healthy aging adult, and only becomes an issue in situations of severe T cell 
depletion, such as HSCT treatment, chemotherapy, or AIDS.25 In addition, some pre-treatment regimens 
such as chemotherapy for patients undergoing HSCT can damage the thymus, further reducing its 
abilities and altering the balance between negative and positive selection, allowing more reactive cells 
through the thymus into circulation, in conjunction with GVHD, which initiates further thymic 
destruction in the host due to donor T cell attack of the thymic epithelium.8,20 In essence, the thymus 
gradually loses its ability to eliminate all self- reactive T cells from the repertoire during negative 
selection. These alterations in selection may reduce the ability of T cells in aged individuals to fight 
infections and cancer. Therefore, in young adults, thymopoiesis is the most common route for the 
generation of peripheral T cells, whereas with age, proliferation of existing T cells must be utilized to 
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maintain T cell numbers, in combination with potentially thymus- independent mechanisms to allow 
maturation of T cells.21,24 Early after HSCT, before the damaged thymus has had an opportunity to 
reconstitute T cells, T cell numbers must be maintained by division of mature donor T cells if few new T 
cells are being produced.11,21 The likelihood of the utilization of peripheral expansion as opposed to 
thymopoiesis as a route to replace depleted T cell populations in HSCT patients grows increasingly 
higher with age and thymic damage associated with treatment, although small amounts of thymopoiesis 
are still possible.21,24,25 Studies have shown that both expansion of donor- derived T cells and the 
generation of new T cells are both present following HSCT, however, the generation of new T cells 
generally takes time associated with the regain of thymic function in conjunction with the slow 
replacement associated with old age. 11,24,27,28 Thymic reconstitution in an aged adult following HSCT 
may take years.21 In addition, T cells take longer than other cell populations such as B cells and natural 
killer cells to recover from lymphopenia.11,21  In a transplant setting, stem cells are mobilized in the 
donor prior to removal for transplant, and are therefore also transplanted into recipient with T cells. In 
this event, the thymus is less effective in assisting the development of T cells from this stem cell 
subset.22,24 Since all the patients considered in this study are well past adolescence (the youngest patient 
being 44 years old), development of donor stem cells into T cells occurs very slowly. 21 Restoration of a 
normal TCR repertoire can take years to re-establish following lymphodepletion. 11  
Two factors that could assist with the reconstitution of thymic function and therefore new T cell 
generation following transplant are inductive cytokines and the generation of more room for growth of 
new T cells in the recipient microenvironment, in addition to the potential of the existence of an 
extrathymic compartment for the maturation of T cells from CD34+ stem cells.31 Although HSCT 
conditioning treatments and GVHD both cause thymic destruction, they also induce an increase in 
cytokines, some of which may help to boost thymic activity (interleukin-7).25,29,30  
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Extrathymic development of T cells is another potential route for the regeneration of the T cell 
population in adults, but has not yet been definitively demonstrated in aged adults as a major contributor 
to T cell reconstitution following lymphodepletion.2,31 It has been shown in mice, however, that 
engrafted thymocytes can go on to develop into lymphocytes in the lymph nodes of irradiated athymic 
recipients in mice.32 In addition, these athymic mice can reject allogenic cancer cells. 33 Extrathymic 
development has been demonstrated in children who have undergone HSCT as well as in healthy 
adults.31,34, 35 Extrathymic T cells are inherently different than thymic T cells in that they react more 
readily to antigen encounter (in terms of proliferation rate and cytokine secretion) but also have a faster 
turnover due to increased susceptibility to apoptosis.36,37 Extrathymic T cells have been shown to 
undergo the elevated homeostatic proliferation necessary for a rebound from lymphodepletion. 31,34,38,39 
Finally, studies have shown that autoreactive extrathymic T cells of the innate immune system (such as 
those found in GVHD) are more likely to be activated during events of thymic atrophy, such as HSCT 
conditioning and GVHD. 40,41  
 
 
Materials and Methods 
Patients 
As shown in Table 1, thirteen patients with hematological malignancies who underwent 
hematopoetic stem cell transplantation (HSCT) were included in this study. From those patients, four 
had non-hodgkin’s Lymphoma (NHL) (patients 3, 7, 9, and 13), four had multiple myeloma (MM) 
(patients 4, 11, 12, and 14), three had chronic lymphocytic leukemia (CLL) (patients 5, 6, and 24) and 
two had prolymphocytic leukemia (PLL) (patients 8 and 16). Peripheral blood stem cells were collected 
from the donor (after stem cell- mobilization followed by apheresis) in order to provide a baseline 
10 
 
sample following engraftment and full donor T cell chimerism (percentage T cells within recipient that 
originate from donor T cells) in recipient. Recipient whole blood samples were collected both prior to 
(“R” sample) and at different timepoints following HSCT (R2, R3, R4). As shown in Table 2, in patients 
that did not have the complication of GVHD, the R2 sample was taken three months following 
transplant and the R3 sample was taken a year following transplant. In the GVHD group, however, R2 
or R3 represents the time of clinical manifestation of GVHD. In patient 5, 6, and 9 GVHD was also 3 
months following transplant, whereas in patients 11, 13, 14, and 24, GVHD manifested earlier, and the 
samples were taken 2 months following transplant. R3 samples were at 3 months for GVHD patients 11, 
13, and 14, four months for patients 8, 9, and 24, and at 5 months for patient 6 (patient 5 deceased prior 
to an R3 sample). A sample at timepoint R4 was obtained for patient 6 (8 months following HSCT), 
patient 9 (1 year), patient 13 (6 months), and patient 14 (6 months).  
 
Representative Patient Selection 
From the 13 patients for which high- throughput data was available, four representative patients 
were selected for analysis: two that had clinical GVHD symptoms and two GVHD- free patients. The 
GVHD and GVHD- free patient groups were divided into two subsets in order to get the most diverse 
range of patient variability as possible. From the GVHD group one patient was selected that 
demonstrated persistent GVHD following treatment (patient 14) and a second that had GVHD which 
resolved after treatment (patient 9) (Table 2). From the GVHD-free group one patient was chosen that 
had full chimerism of the donor’s T cells (patient 3) and one that did not have full chimerism at the R2 
timepoint (delayed full chimerism) (patient 4). All GVHD patients had approximately full donor T cell 
chimerism (Table 3). All samples that were utilized for analysis were sequenced with over 95% 
productivity (9R2 sample was eliminated due to low productivity) (Table 4). Patient 9 had no HLA 
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mismatches with the respective donor whereas patients 14 and 3 both had one mismatch, and patient 4 
had four HLA mismatches with their respective donors (Table 1). Patients were analyzed in pairs so that 
each GVHD patient was analyzed with each GVHD-free patient, resulting in four GVHD-GVHD-free 
pair groups.  
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Table 1. Patient characteristics 
 
Patient 
Age/ 
sex disease 
prior 
autologous 
HSCT  
disease 
status 
at 
HSCT 
Donor 
age/ 
sex Donor 
Donors non-identical 
HLA alleles  
Recipients non-identical 
HLA alleles 
              class I class II class I class II 
5 
58/M CLL No CR 36/M URD none none none none 
6 68/M CLL No CR 63/M MRD 
A-
01CZRH, 
B- 
08DDHN, 
44DDHW   
A- 0101, B- 
0801,4402, 
Cw-0501, 
07WTR  
DQB1-
0301, 0302 
DRB4- 
01ZDV 
8 
57/M PLL No CR 40/M URD none 
BRB3-
02CYUC none 
DRB3- 
02AMCC 
9 55/M NHL Yes CR 65/F URD none none none none 
11 58/F MM Yes PR 70/M MRD Cw-0304   Cw- 0302 
DRB1- 
0201, 0301, 
DRB3- 
01USC, 
DRB4- 
01ZDV 
13 59/F NHL No CR 22/M URD B-44HTH 
DQB1-
0302 B-440201 DQB1-0301 
14 56/M MM Yes PR 43/F URD B-5601 none B-15GYF none 
24 58/M CLL No PR 47/F URD none none none none 
3 
44/F NHL No CR 32/M URD none 
DQB1-
0503 none   
4 
46/F MM Yes PR 52/F MRD none 
DQB1-
02GM none 
DQB1-
0201, 
DRB3-
02CYUC, 
DRB4-
01ZDV 
7 56/F NHL No CR 46/F URD none 
DQB1-
0301 none DQB1-0302 
12 62/M MM Yes PR 20/M URD 
B- 
07ANVB none B- 070201 none 
16 62/M PLL No CR 65/M MRD none   none 
DQB1-
0202, 0602, 
DRB4- 
01ADH, 
DRB5-0101 
G
V
H
D
 
G
V
H
D
- f
re
e 
 
 
 
 
 
 
 
CLL: chronic lymphocytic leukemia; PLL: prolymphocytic leukemia; MM: multiple myeloma; NHL: 
non-Hodgkin lymphoma; PR: partial response; CR: complete response; MRD: matched related donor; 
MUD: matched unrelated donor; URD: unrelated donor 
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Table 2. GVHD patient progression 
 
Patient 
number - 
disease 
R2 R3 R4 R5 current status 
5 - CLL  
aGVHD delayed onset: 
persistent, IV (3 mo); 
skin grade 2-3 
progressed to GI grade 
4 
deceased 7/5/2009 
(day 162)     
died of infection 
6 - CLL No GVHD (3 mo.)  
acute; grade 4 gut 
aGVHD (5 mo)  
7/14/09 (late onset, 
IV) 
Gut GVHD was 
resolved at 8 mo 
but chronic 
cutaneous GVHD 
(1 y) 
cGVHD: 9/30/2010  
deceased 
10/25/2011 (979 
days after SCT) 
death cause 
unknown, 
assumed to be 
sepsis 
8 - PLL No GVHD (3 mo)  GVHD (4 mo) GVHD resolved  (6-8 mo) 
Deceased 
4/27/2010 (404 
days after SCT) 
GVH resolved at 1 
year 
death due to 
multi organ 
failure post 
hemolytic 
anemia and 
splenectomy 
9 - NHL No GVHD (3 mo.)  cGVHD (4 mo)  skin GVH resolved  (1 y)    
alive  
11 - MM  cGVHD (2 mo.); GVH - skin 
cGVHD (3 mo.); skin 
GVHD  resolved  b/w 
4 and 6 mo after R3 
cGVHD (1 y) lung and mouth GVHD 
alive in CR 
13 - NHL  
aGVHD grade I (2 mo) 
(3/18/2010).; acute 
classical skin grade 1; 
delayed onset 
persistent grade III  
delayed onset 
aGVHD progressive 
(3 mo), skin  
GVHD resolved 
(6 mo) 
(6/10/2010)  
1 year (1/18/2011) 
GVHD resolved 
alive in CR 
14 - MM  cGVHD (2 mo); chronic skin  
3 mo.5/20/2010 
GVHD developed on 
6/17/10 
(6/22/2010.); skin 
and rectal GVHD 
aGVHD delayed 
onset (4 mo)      
6/24/2010: gut 
GVH 
deceased day 171 
DOD: 8/3/2010  
(6 mo) death due to 
infection- steroid 
refractory GVHD 
24 -CLL 
aGVHD skin grade 1- 
4/27/2011 acute gut 
7/12/2011 
day 100 (6/7/11); 
esophagus GVHD 
(6/14/11); colon grade 
I to II (6/15/11) 
    
ISP taper, 
remission 
 
CLL: chronic lymphocytic leukemia; PLL: prolymphocytic leukemia; MM: multiple myeloma; NHL: non-
Hodgkin lymphoma; PR: partial response; CR: complete response; MRD: matched related donor; MUD: 
matched unrelated donor. Roman numerals indicate GVHD classification. 
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Table 3. Recipient donor T cell chimerism 
 
 
 
 T cell chimerism 
(months after SCT) 
Patient 
R2 R3 R4 
5 0% (3) Deceased day 162  
6 0% (3) 0% (5) 0% (12) 
8 1.6% (3) 2.5% (4) 6.4% (12) 
9 2.2% (3) 1.6% (4) 0% (12) 
11 0% (2) 0% (3) 0% (12) 
13 0% (2) 0% (3) 0% (5) 
14 0% (2) 1.5% (3) 0%(4) 
24 0% (3) N/A N/A 
3 10.9% (4) 0% (13) N/A 
4 51.3% (3) 8% (11) N/A 
7 51.5% (3) 62.9% (10) N/A 
12 8.6% (3) 0% (12) N/A 
16 4.7% (3) 29.8% (6) N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G
V
H
D
 
 
 
 
 
 
 
 
G
V
H
D
-fr
ee
 
Percentages indicate the proportion of T cells that are not from the engrafted donor T cells (recipient T cells). 
N/A: not available 
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Table 4. Percent of productive sequences for each sample analyzed  
 
     
Patients         
  D R2 R3 R4 
5 97.967 98.837 
NS NS 
6 96.89 100 98.359 97.242 
8 
96.975 99.587 98.513 NS  
9 95.909 24.324 97.918 98.08 
11 97.755 97.055 97.023 NS  
13 96.469 97.874 NS 98.445 
14 96.795 97.716 98.185 98.442 
24 96.559 98.308 98.812 NS  
          
3 
97.831 97.593 98.734 
NS 
4 97.237 93.459 96.128 
NS 
7 97.554 98.558 98.307 
NS 
12 90.995 98.209 97.867 
NS 
16 96.397 96.319 NS  
NS 
G
V
H
D
 
G
V
H
D
-fr
ee
 
 
 
NS: No sample sent for analysis 
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T cell isolation and mRNA extraction 
Recipient samples (R2-R4) were obtained at the aforementioned timepoints and RNA was 
extracted as previously described by our group.10 Following a 1:1 dilution in salt solution (1X HBSS), 
recipient samples were layered on Ficoll-PaqueTM premium (GE Healthcare) to create a density gradient 
upon centrifugation (according to the manufacturer’s protocol). Following centrifugation, the buffy coat 
containing mononuclear cells was isolated, washed, and incubated for 2 hours at 37ºC 5% CO2 with 
0.1% autolougous serum and RPMI medium. Following incubation, non- adherent cells (lymphocytes) 
were collected and CD3+ cells isolated using EasyStep® Negative Selection Human T cell enrichment 
Kit according to the manufacturer’s protocol (Stem Cell Technologies).  
The procedure for CD3+ isolation differed for donor samples due to the nature of extraction 
efficiency for CD34+ cells. It was determined previously that high yields of CD3+ cells could be 
obtained from unfractionated CD34+ donor stem cells from peripheral blood following stem cell 
mobilization using granulocyte colony- stimulating factor (G-SCF) and apheresis.10 For this reason, the 
T cell enrichment kit was not used for donor samples, and samples were cultured in serum- free medium 
for two hours and RNA was extracted from non-adherant cells as discussed above.   
RNA was extracted from isolated CD3+ stem cells using Trizol (Invitrogen) according to 
manufacturer’s protocol. To eliminate contamination of RNA sample with DNA, DNase treatment was 
applied using RQ1 RNase-free DNase (Promega, according to manufacturer’s protocol). Superscript II 
reverse transcriptase (Invitrogen) was then used to create double- stranded complementary DNA 
(cDNA) by incubating 1µg of the total RNA extracted with a dT18 oligonucleotide primer to 
specifically amplify polyadenylated mRNA. Synthesis of cDNA was accomplished by incubating for 2 
hours at 42ºC in a thermocycler. To confirm purity of samples prior to high- throughput analysis, RNA-
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derived cDNAs were subjected to PCR analysis of GAPDH. The PCR products were then run on 1% 
agarose gel. A bright, clear band indicated a pure product with minimal degradation.  
 
High throughput sequencing of TCR Vβ 
Upon confirmation of pure product, 1- 119ug (average of 55ug) per sample of cDNA (depending 
on how much mRNA was initially extracted) was sent to ImmunoSEQ (Seattle,WA) for high-throughput 
molecular analysis of the CDR3 region. The deep- level analysis provided by ImmunoSEQ is capable of 
uncovering approximately 8,000,000 sequences per sample (targeted output).42 By utilizing 52 forward 
primers for the Vβ gene segment and 15 reverse primers for the Jβ segment, the multiplex PCR system 
is able to capture an entire VDJ recombination.43 The primers are designed to accommodate a 60 base 
pair read, and since an average CDR3 region is around 35 base pairs, this technique includes most 
known CDR3 regions. 42,43 There are, however, rare cases in which very long or very short CDR3 
regions are not captured. 42 
ImmunoSEQ utilizes a Genome Analyzer (GA) system as a platform for the sequencing that is 
conducted. The GA system works by hybridizing the template molecules (with a universal PCR adapter 
added) to a lawn of primers that are anchored to a stable base. Following hybridization, PCR amplifies 
the cDNA, forming clusters consisting of millions of replications of the template molecules that can then 
be sequenced.42 Sequencing is done by the subsequent and repeated incorporation of fluorescent 
nucleotides followed by imaging of the nucleotide that is incorporated after each round of addition. The 
fluorescence is indicative of which nucleotide was incorporated at each step. This cycle is repeated until 
the entire molecule is sequenced. Figure 1 demonstrates how this process works while Figure 2 
demonstrates how sequencing is conducted.44 All samples were normalized for PCR bias, which 
accommodates for a select few V and J primers that amplify more or less efficiently than others.  
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Figure 1. Genome Analyzer system44 
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Figure 2. The process of high-throughput sequencing44 
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Generation of spectratyping graphs 
Clonality data was derived from spectratyping graphs generated from TCR VJ recombination 
analysis obtained from ImmunoSEQ in the following manner: From ImmunoSEQ website 
(www.immunoseq.com) single sample analysis of each individual sample was selected, normalized for 
PCR bias, (all data analysis included this normalization) and visualized as a 3-D histogram. Upon 
exportation of data, graphs were generated for each individual VJ gene for each patient at each 
timepoint. This data set was used to determine clonality as well as fold increase over that of donor for 
each individual VJ recombination of interest at a later point in analysis. 
 
Identification of GVHD-associated T cells based on clonality of TCR VJ gene recombination 
rather than the frequency of TCR Vβ family at each timepoint 
In previous analysis in our lab, significant clones were selected by increases in the expression of 
TCR Vβ family in recipient over those in respective donor using qRT-PCR technique, which may have 
far- reaching implications in terms of the ability to uncover all critical clones.10 TCR Vβ families 
include not only all variations of a particular V gene for that family, but also all 13 J gene combinations 
with each V gene. So while allowing for a great overall depiction of increase within a Vβ family, this 
type of analysis does not pinpoint particular VJ combinations that are relevant. Addressing only 
increases by Vβ family results in overlooking relevant clones at a molecular level (VDJ recombinations) 
due to high counts of some irrelevant VDJ recombinations which may mask disease-associated clones 
within Vβ families. Focusing on clonality of VJ recombination by taking a more fine- tuned approach 
using high throughput sequencing technology, on the other hand, will uncover all relevant T cell clones 
that are reacting with target antigens. As demonstrated in Figure 3, there are Vβ families such as Vβ 
families 4 and 13 in patient 9 that increase while overshadowing other individual VDJ recombinations 
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that may also be relevant. This occurs when proliferation of a particular Vβ family is so large that a 
graph depicting fold increase makes that particular family stand out while neglecting to include those 
clones that could be relevant due to mono- or oligo-clonality compared to that of donor. Therefore, by 
addressing only Vβ families, many individual VJ recombinations that have a massive increase from 
donor in addition to clonality are still potentially overshadowed and excluded from further examination.  
In addition, while there may be Vβ families that do not increase from that of donor, increase of 
particular VJ clones within that Vβ family are detectable at a molecular level. As demonstrated in 
patient 9, although there is no fold increase (decimal points as fold-increase data on Y-axis indicate a 
decrease from donor) from the donor of the Vβ families 10 and 14 (Figure 3), there is clonality (Figure 
4) and increases of clones within that family from that of donor (Figure 5). Only exploration of clones at 
a molecular level could uncover these seemingly small fluctuations in particular TCR Vβ’s that could be 
critical in disease manifestation. This is why clonality was addressed prior to that of fold increase over 
donor in this study. By selecting clones based on clonality first, we automatically exclude those clones 
that are increased as a result of homeostatic proliferation and leave only antigen- reactive clones.  
 
Revealing proportions of donor- derived stem cells and T cells 
Upon uncovering those clones that were both clonal and followed a trend in clonality that 
correlated with GVHD progression, the sequences were broken down at a molecular level into those 
clones that were expressed in both donor and recipient (shared clones derived from the expansion of 
donor’s T cells) at any timepoint and those that were expressed in only the recipient (unique clones 
derived from new TCR recombination of donor’s stem cells). This division was conducted based on the 
knowledge that at full chimerism in recipient, any T cell that is not shared with donor has been newly 
generated from engrafted donor stem cells.  
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Before this could be completed, however, the next important step was to determine which 
recipient sample timepoint was best suited for a more in- depth analysis. Using the same numbers from 
the previous spectratyping analysis, the recipient timepoint with the highest count and full donor T cell 
chimerism for the VJ recombination of interest was selected. If selection was on a GVHD patient, only 
those timepoints in which clinical manifestation of GVHD was present were considered. This was done 
by filtering those files derived from a multiple sample analysis including all sequences in order to 
uncover all variations of a VJ recombination at a molecular level. Selecting for “intersection of samples” 
in the filtering tab during a multiple sample analysis on the ImmunoSEQ website for the donor sample 
and all recipient (R) samples for a particular patient, all sequences expressed in any of the samples are 
given. This allowed for the exposure of all sequences that are expressed at any timepoint, as opposed to 
only those sequences that are shared at all timepoints (“union” of samples).  
 
Obtaining top 20 donor- derived T cell and stem cell clones 
Following division of the select VJ recombinations of interest, fold increase over the donor as 
well as frequency of such shared and unique clones was then determined. For those clones that were 
unique to recipient (stem cell origin), the top 20 VDJ recombinations were selected from the previously 
determined timepoint based on either highest count (patients 3 and 14), full chimerism (patient 4), or the 
presence of clinical manifestation of GVHD (always R3 for patient 9 and the timepoint with the highest 
count for patient 14). For T cell clones shared between donor and recipient, the top 20 clones that 
showed the highest increase from donor at the same timepoint (described above) utilized to derive stem- 
cell top 20 clones were collected as well as frequencies of those top 20 clones. 
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Figure 3. Changes in the expression of TCR Vβ family in GVHD patient 9 when compared with 
respective donor. Fold increases in expression of 30 human TCR Vβ families over respective donor 
was analyzed in GVHD patient 9 at the time of GVHD (R3) and after GVHD was resolved (R4).  
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Figure 4. Clonality of TCR Vβ is associated with GVHD. Spectratyping analysis of TCR Vβ 10-1 and 
TCR Vβ 14 are shown in donor and respective recipient of GVHD patient 9 at the time of GVHD (R3).  
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Figure 5: Top T cell VDJ recombinations over that of respective donor in GVHD patient 9. Upon 
in-depth exploration of clonal VJ recombinations at a molecular level, relevant VDJ amino acid 
sequences can be uncovered based on fold increase over respective donor.  
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Results 
 
TCR VJ clonality can identify GVHD- associated clones 
Previous studies in our lab showed that certain TCR Vβ’s were associated with both GVHD and 
GVHD-free survival.10 In order to determine whether these T cell clones may differ at molecular levels 
we performed high throughput sequencing of 30 human TCR Vβ’s (52 V gene segments) and 13 J 
genes.  Single sample analysis of Vβ family normalized for primer bias exported to excel was used to 
generate spectratyping data of donors and recipients T cells at different timepoints following HSCT.  
From spectratyping analysis, we selected those clones that were mono- or oligo- clonal 
associated with clinical manifestations of the disease, GVHD, and compared them to those clones that 
were also clonal in GVHD- free patients. As demonstrated in Figure 6, there were four VJ 
recombinations (TCR Vβ4-3 J1-1, V7-9 J2-7, V10-1 J2-1, and V14 J2-1) in patient pair 9 and 3 that 
were deemed significant based on shared clonality between patients and/ or change in clonality pattern 
following GVHD resolution at R4. TCR Vβ4-3 J1-1, V7-9 J2-7, and V14 J2-1 are demonstrations of an 
altered clonality pattern in addition to decrease from donor at the R4 timepoint (Figure 6a, b, d), while 
TCR Vβ V10-1 J2-1 maintains a similar clonality pattern, though with lower counts at R4 compared to 
R3 (Figure 6c). The same procedure was applied to the remaining patient pairs with similar results. 
Patient 9 was compared to patient 4, who initially had delayed donor T cell chimerism at the R2 
timepoint, which resolved at R3 (Table 3). As shown in Figure 7, three clones (TCR Vβ7-1 J2-1, V7-9, 
J2-1, and V14 J2-1) were selected based on the same criteria as mentioned above (shared clonality and 
potentially altered patterns of clonality upon GVHD resolution). Within these three clones, V7-9 J2-1, 
and V14 J2-1 demonstrate an alteration of clonality pattern upon GVHD resolution (Figure 7b, c) while 
TCR Vβ V7-1 J2-1 maintains a similar clonality pattern over time, although with substantial decreases 
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in numbers (Figure 7a). A similar trend in clonality alteration is seen in the corresponding GVHD-free 
partner within the pair, patient 4 (Figure 7a-c). Clonality pattern is unaltered in TCR Vβ 7-1J2-1 (similar 
to patient 9) and V14 J2-1 (as opposed to the change in clonality seen in patient 9) at full donor T cell 
chimerism (R3) while a change in the pattern of clonality is seen in V7-9 J2-1 (Figure 7c).  
  As representative patient pairs, comparative analyses of TCR Vβ with patient 14 (who had 
persistent and progressive GVHD until death, see Table 2) were also performed. Patient pair 14 and 4 
had four VJ recombinations shared (TCR Vβ 4-1 J 2-7, V6-1 J1-5, V7-9 J2-1, and V11-2 J2-1) (Figure 
8) which were all deemed relevant based on shared and skewed clonality. Clones were considered if 
they exhibited clonality at any timepoint in the GVHD patient, since GVHD was manifest at all three 
timepoints (R2, R3, and R4). In patient 14 in Vβ 4-1 J2-7 (Figure 8a), clonality increased from R3 to 
R4, with the pattern of clonality remaining the same, whereas in V11-2 J2-1 (Figure 8d) although the 
clonality pattern also remained the same, the numbers of that particular recombination increased 
substantially. V6-1 J1-5 does not emerge until R4, and a defined clonality is also not observed until this 
timepoint, indicating not only its dominance over other clones later in manifestation but also its potential 
relevance at later stages of GVHD (Figure 8b). Finally, V7-9 J2-1 has a similar pattern of clonality 
throughout the timepoints, with the pattern growing more clonal as disease progresses (Figure 8c).  
To complete analysis of all representative patient pairs, the final pair to be discussed is patient 
pair 14 and 3, which had three relevant clones selected based on shared clonality which include V4-1 J2-
7 (Figure 9a), V5-6 J1-1 (Figure 9b) and V7-8 J2-7 (Figure 9c). In both V4-1 J2-7 and V7-8 J2-7 in 
patient 14, clonality becomes progressively more defined at each timepoint (Figure 9a and Figure 9c), 
which is critical for the maintenance of clinical manifestation of GVHD in a competitive internal 
environment. The patterns of clonality also persist in the corresponding GVHD-free patient within the 
pair. 
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Figure 6. TCR Vβ’s are selected based on clonality and shared status between patients 9 and 3. 
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 9 
and GVHD- free patient 3. Analyses were performed three months after HSCT for patient 3 and at the 
time of GVHD (R3) and GVHD resolution (R4) for patient 9. 
A. Vβ 4-3 J1-1  
B. Vβ 7-9 J2-7 
C. Vβ 10-1 J2-1 
D. Vβ 14 J2-1 
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Figure 7. TCR Vβ’s are selected based on clonality and shared status between patients 9 and 4. 
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 9 
and GVHD- free patient 4. Analyses were preformed three months after HSCT for patient 4 and at the 
time of GVHD (R3) and GVHD resolution (R4) for patient 9. 
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Figure 8. TCR Vβ’s are  selected based on clonality and shared status between patients 14 and 4. 
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 14 
and GVHD- free patient 4.  Analyses were performed three months after HSCT for patient 4 and at the 
time of progressing GVHD (R2, R3, and R4) for patient 14. 
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Figure 9. TCR Vβ’s are selected based on clonality and shared status between patients 14 and 3. 
Spectratyping analysis of TCR Vβ’s are shown in donor and respective recipients of GVHD patient 14 
and GVHD- free patient 3. Analyses were performed at three months after HSCT for patient 3 and at the 
time of progressing GVHD (R2, R3, and R4) for patient 14. 
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GVHD- related TCR VβJ clonality is not always associated with an increased frequency in 
recipient over the donor at the onset of GVHD for all individual VJ recombinations 
From each Vβ spectratyping graph, those clones that were both clonal and shared between each 
patient pair were selected and examined for change in frequency from donor. If a particular VJ 
d significant in the GVHD m the GVHD-
oints 
ient 9, who 
had res
Figures 7b and c), V4-1 J2-7, V6-1 J1-5, V7-9 J2-1 (p
recombination was foun patient, the corresponding clone fro
free patient was also analyzed. In the case of p t GVHD (patient 14), any of the three timep
(R2, R3, R4) was considered for analysis, since GVHD was present in all samples. For pat
ersisten
olution of GVHD at the R4 timepoint, only clones that were present at R3 and decreased at the 
R4 timepoint were considered (the R2 timepoint was eliminated due to low productivity of sequencing). 
A decrease at the time of GVHD resolution (timepoint R4) was therefore a criterion for inclusion in 
patient 9. Both timepoints were considered for GVHD- free patient 3, and only the timepoint with full 
donor T cell chimerism was considered for GVHD-free patient 4 (R3). 
Using the same data set that was utilized to create the spectratyping graphs, changes in the 
frequency of GVHD-associated clones were determined. This allowed for the determination of alteration 
of counts of a particular VJ recombination compared to that of donor. This analysis showed that 
clonality in spectratyping did not always translate into an increase from donor at the time of GVHD. For 
instance, V7-9 J2-7, V10-1 J2-1, V14 J2-1 (patient 9, Figure 6b-d), V7-9 J2-1 and V14 J2-1 (patient 9, 
atient 14, Figure 8a) and V5-6 J1-1 and  V7-8 J2-7 
(patient 14, Figure 9c), showed skewed clonality, however, these clones did not increase at the time of 
GVHD (R3) while decreased (patient 9) or persisted (patient 14) at the resolution or persistence of 
GVHD at R4, respectively (Figures 10a and b). In contrast, all of these clones (Figure 10), except V11-2 
J2-1 (Figure 10b, upper right panel), and V4-1 J2-7, and V7-8 J2-7 (Figure 10b, lower right panel) 
increased in GVHD-free patients 3 or 4 (Figure 10b). 
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In addition, there were also clonal T cells that increased in patients compared to their respective 
donors at the time of GVHD (R3) and decreased or persisted at the resolution or persistence of GVH
(R4), respectively. For instance, V7-1 J2-1 (patient 9, Figure 10a) and V11-2 J2-1 (patient 14, Figure 
10b) increased at the time of GVHD (R3) and decreased (patient 9) or remained at high levels (patie
14) at the resolution or persistence of GVHD (R4), res
D 
nt 
pectively (Figures 10a and b). V4-3 J1-1 (patients 
9, Figu
d 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
re 10a) increased at R3 but did not show appreciable decrease when GVHD was resolved at R4 
(Figure 10a, upper left panel). V4-1 J2-7 also increased at R4 in patient 14 when GVHD persisted but 
not at R3 when GVHD appeared (Figure 10b, upper left panel). In contrast, V4-1 J2-7 (in patient 3) an
V11-2 J2-1 (in patient 4) did not increase over the donor in GVHD-free patients (Figure 10b, right 
panels). V4-3 J1-1 increased at R2 and decreased one year after HSCT in GVHD-free patient 3 (Figure 
10a). Again, these data suggest differences in the trend of frequency of these shared clones in GVHD vs
GVHD-free patients. These data also suggest that further molecular analysis of TCR Vβ is needed to 
determine whether relevant VDJ recombination associated with GVHD may differ from those in 
GVHD-free patients.   
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Figure 10. Alterations of counts of select VJ recombinations shared between GVHD patients and 
GVHD-free patients. Numbers of different VJ recombinations in each clonal population were 
etermined in GVHD patients 9 (A) and 14 (B) as well as GVHD-free patients 3 and 4. 
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TCR Vβs that showed clonality and were shared between patients with GVHD and GVHD- free 
atients differ at a molecular level from one another in both amino acid sequence and increase in 
xpression from donor following HSCT 
Similarity in trends of clonality provides the justification for high- throughput analysis in order 
 uncover those individual VJ recombinations that are contributors to clinical manifestation of GVHD. 
More detail is needed to uncover individual relevant clones that show persistent increase in frequency 
associated with both GVHD and GVHD-free status in order to uncover which exact VJ recombinations 
are relevant to GVHD. In those clones that were deemed relevant based on shared clonality and trends, 
variability existed upon examination at a molecular level of the number of critical clones. In most cases 
there were fewer different donor- derived TCR VβJ sequences that had higher frequencies overall.  
As discussed above, patient 9 developed GVHD at R3, and GVHD was resolved at R4. This 
patient represents responsiveness to the treatment and can be compared with GVHD-free patient 3 (both 
had full chimerism) for VDJ molecular analysis to identify unique GVHD-associated VDJ 
recombinations based on increase at R3 and decrease at R4. There were also two different conditions in 
GVHD patient 9 where some clones did not increase over the donor but decreased upon GVHD 
resolution (Vβ14 J2-1, Figure 10a) and some clones increased over the donor but did not decrease 
significantly upon GVHD resolution (Vβ4-3 J1-1, Figure 10a). Molecular analyses of these two clones 
were performed in order to determine that shared clones associated with GVHD and GVHD-free differ 
and GVHD-free patient 4. 
Given that donor- derived stem cells contained both T cells and stem cells, the number of 
different VDJ sequences for both donor- derived T cells and newly formed T cells from donor stem cells 
p
e
to
at molecular levels, i.e. VDJ recombinations, and that changes in the frequency of GVHD-associated 
clones may be revealed at the molecular levels. We also performed similar analysis in GVHD patient 14 
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in recipient microenvironment was identified by filtering for presence/ absence of each individual 
sequence at each timepoint in the recipient. As shown in Figure 11, there were two donor-derived T cell 
types in shown 
p 
mber 
e 
ore relevant than the others in terms of disease manifestation or GVHD- 
free su
 
 
 
der 
 the recipients 3-4 months after HSCT: those expanded from donor T cells (shared T cells 
in brown color) and those derived from donor stem cells and underwent VDJ recombination in the 
recipients (unique T cells shown in blue color). From both the stem cell and the T cell subset, the to
twenty clones were analyzed.  
In the analysis of T cell clones that were shared between donor and recipient comparing GVHD 
patient 9 and GVHD-free patient 3 (Figure 12a) , both Vβ 4-3 J1-1 and Vβ 14 J2-1 had a limited nu
of clones that were significantly higher in terms of fold increase than in their donor counterparts. Thes
clones were considered to be m
rvival due to their marked size in fold increase from donor compared to the others within the top 
twenty. In the case of donor-derived T cell clones (shared sequences between donor and recipient), 
GVHD patient 9 showed seven different VDJ sequences in V4-3 J1-1 that demonstrated increases over 
respective donor at the time of GVHD whereas GVHD-free patient 3 had a higher diversity of different 
V4-3 J1-1 clones (Figure 12a).  Importantly, the three V4-3 J1-1 clones that showed 100-400 fold 
increases over respective donor in GVHD patient 9 were distinct from the three different V4-3 J1-1 
clones that showed 100-900 fold increases in GVHD-free patient 3 over respective donor. Similarly, 
three different V14 J2-1 clones that showed 100-900 fold increases in GVHD patient 9 over their 
respective donor differed from the three different clones that increased 20-170 folds in GVHD-free
patient 3 over their respective donor.  These data confirm that clonality and increases in certain TCR
Vβ’s transferred from respective donors in both GVHD and GVDH-free patients are not indicative of
cross reactivity of T cells with tumor cells and self cells. Rather, distinct T cell clones (VDJ 
recombinations) may be associated with reactivity against tumor cells and self cells separately. In or
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to determine whether different VDJ recombinations of these two clones that had highest frequencies i
each patient may be specific to each patient, the top 20 sequences with highest frequencies were also 
analyzed of the same shared (T cell derived) VJ recombinations shared between GVHD and G
patients (Figure 12b). As shown in Figure 12b, these shared clones with the highest frequencies in each 
patient (>0.2% within V4-3 J1-1 and >0.05% within V14 J2-1) did not show any similarity between 
GVHD and GVHD-free patients.   Frequency of these T cell clones in the recipients are also shown in
Figure 12b in order to demonstrate not only the much higher scales (Y- axis) but also the greater 
diversity in frequencies from stem- cell derived T cells (Figure 13). 
Differences in minor histocompatibility antigens (mHA) in individuals suggest that newly 
recombined T cells following HSCT would be different at molecular levels between GVHD and GVHD
free patients. To test this, top 20 VDJ recombinations that were unique to the recipients 3-4 month
HSCT but were absent in their respective donors were analyzed. As s
n 
VHD-free 
 
-
s after 
hown in Figure 13, five different 
V4-3 J  cell 
 
atient 
lls in 
4 
ed from donor T cells in patient pair 9 and 3 [one of which is 
1-1 clones showed highest frequencies in GVHD patient 9 (over 0.001%) compared to all T
recombinations in this patient. On the other hand, only two different clones showed such a high 
frequency (over 0.001%) in GVHD-free patient 3. Sequence analysis of these clones showed no 
similarity between these higher- frequency clones. Similar observations were made analyzing V14 J2-1
in GVHD patient 9 and GVHD-free patient 3.  Similar observations were made comparing GVHD 
patient 9 and GVHD-free patient 4 (Figure 14 and 15) as well as the other patient pairs GVHD p
14 vs. patient 3 and 4 (Figures 16-19). 
 Few sequences in the selected top twenty VDJ recombinations matched exactly one another 
between GVHD and GVHD- free patients. Among these, two sequences were derived from stem ce
patient pair 4 and 9 (Figure 14- CASSSDYLGPGSSAYNE in V7-1 J2-1 and CASSPSGRGYNE in V1
J2-1). In addition, four sequences deriv
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shown in Figure 12- CASSQVAFSYNE {V14 J2-1}]), and of those, none from the top relevant 
recombinations matched one another. In other words, from those select clones that did, in fact, exactly 
match one another in terms of amino acid sequence, both would not be found within the selected top 
relevant clones. Only one exception was found between patient pair 9 and 3 V4-3 J1-1 (Figure 12a, fi
column) (CASSPSRNTE).   
 
cells and T cells derived from donor stem cells. Log scatter plots plotting distribution of donor-
depicts those cells that were newly generated from donor stem cells.  
 
rst 
Figure 11. The distribution of all VDJ recombinations derived from transplant, both expanded T 
derived T cells in recipients 3-4 months after SCT. Brown dots indicate engrafted T cells while X axis 
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Figure 12. Top VDJ sequences that were shared between donor and GVHD or GVHD-free 
ecipients differed at molecular levels.  
. Fold increase of top shared sequences of the relevant clones over that of donor in GVHD patient 9 
nd GVHD-free patient 3 for V4-3 J1-1 and V14 J2-1 at 3-4 months following HSCT 
. Frequency of top shared sequences of the relevant clones in each patient. 
       Patient 9 
 V4-3 J1-1             V14 J2-1 
  
r
 
A
a
 
B
 
A.            
  
     
 
      Patient 3 
        
 
se
 o
ve
r t
ha
t o
f d
on
or
 
Fo
ld
 in
cr
ea
Amino Acid Sequence 55 
 
B.           Patient 9 
          V4-3 J1-1                        V14 J2-1 
 
 
      
Patient 3 
 
     
 
       
 
 
 
 
P
er
ce
nt
 fr
eq
ue
nc
y 
am
on
g 
al
l V
D
J 
se
qu
en
ce
s 
Amino Acid Sequence 
56 
 
Figure 13. Top VDJ sequences that were unique to the recipients differed at molecular levels 
between GVHD patient 9 and GVHD-free patient 3. Top Unique Sequences over that of donor in 
patient pair 9 and 3 for V10 J2-1 and V14 J2-1 (patient 9 at timepoint R3 and patient 3 at timepoint R2) 
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Figure 14. Top VDJ sequences that were shared between donors and recipients differed at 
molecular levels between GVHD patient 9 and e patient 4. Top shared sequences over 
that of donor in patient pair 9 and 4 for V7-1 J2-1 and V14 J2-1 (patient 9 at timepoint R3 and patient 4 
at timepoint R3) 
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Figure 15. Top VDJ sequences that were unique pients differed at molecular levels 
 pati t 9 an  GVH -free atient 4. Top niqu Seque ces ov r that 
patient pair 9 and 4 for V7-1 J2-1 and V14 J2-1 (patient 9 at timepoint R3 and patient 4 at timepoint R3) 
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 Amino Acid Sequence 
Figure 16. Top VDJ sequences that were sha n donors and recipients differed at 
that of donor in patient pair 14 and 4 for V4-1 J2-7 and V6-1 J1-5 (patient 14 at timepoint R4 and 
epoint R3) 
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Figure 17. Top VDJ sequences that were uniqu ients differed at molecular levels 
betwe
patient pair 14 and 4 for V4-1 J2-7 and V6-1 J1-5 (patient 14 at timepoint R4 and patient 4 at timepoint 
R3) 
Patient 14 
V4-1 J2-7           V6-1 J1-5 
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Figure 18. Top VDJ sequences that were shared between donors and recipients differed at 
molecular levels between GVHD patient 14 and GVHD-free patient 3. Top shared sequences over 
that of donor in patient pair 14 and 3 for V4-1 J2-7 and V5-6 J1-1 (patient 14 at timepoint R4 and 
epoint R2) 
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V4-1 J2-7           V5-6 J1-1 
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Figure 19. Top VDJ sequences that were unique to the recipients differed at molecular levels 
between GVHD patient 14 and GVHD-free patient 3. Top unique Sequences over that of donor in 
patient pair 14 and 3 for V4-1 J2-7 and V5-6 J1-1 (patient 14 at timepoint R4 and patient 3 at timepoint 
R2) 
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T cell clones associated with both GVHD and GVHD-free survival fail to show an association 
between donor-derived T cells or stem cells with disease outcome 
In order to determine whether donor- derived T cells (sequences shared between donor and 
recipient) or stem cells (sequences unique to recipient) may predict GVHD, those clones previously 
selected for relevance based on common spectratyping trends were analyzed. The same patient pairs as 
described above were used here in order to create a comparison between patients with GVHD and those 
with GVHD- free survival. In this case, a comparative analysis was conducted between GVHD patients 
9 or 14 and GVHD- free patients 3 or 4 at the same relevant timepoint as utilized in previous analysis 
above. Our hypothesis was that ratios of the stem cell- derived T cells and the engrafted donor T cells 
could provide prognostic value in determining the outcome of disease. Figures 20a-d demonstrates 
numbers of unique T cells derived from donor’s stem cells and numbers of donor’s T cells expanded in 
the recipients at different timepoints following HSCT. Counts were divided based on when they were 
present in the samples ie, if the amino acid sequence was present at R3 only, R4 only, or both R3 and R4 
for stem cell- derived T cells (unique) or if the sample was shared between donor at only the R3 
timepoint or both the R3 and the R4 timepoint for donor- derived T cells (shared). The number of 
different stem cell- derived T cells (unique) was greater than that of shared for every relevant VJ 
recombination examined with only two exceptions in V4-3 J1-1 in GVHD-free patient 3 (Figure 20a) 
and V7-1 J2-1 in GVHD patient 9, (Figure 20 b). There was no consistent association between number 
of unique or shared T cells for all the relevant clones with trend of GVHD in patients 9 or 14. 
The ratio of unique to shared T cells in GVHD patients was then calculated for each timepoint in 
sis may predict disease ou ugh 
d to GVHD-free patients in 
patient pairs 9 vs. 3 and patient 14 vs. 3, such correlation did not exist while comparing patient pair 9 vs. 
order to determine whether such analy tcome. As shown in Figure 21, altho
ratios of unique to shared T cell clones were higher in GVHD compare
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guish 
not 
 
 
 
 
 
 
 
 
tient 14 vs. 4. Patient 3, but not patient 4, had consistently smaller ratios regardless of which 
GVHD patient they are being analyzed alongside of (Figure 16).  
Frequency of each relevant clone in patients was then determined.  Overall frequency refers to 
the percentage of that particular amino acid sequence within the entire 30 different TCR Vβ families at 
each timepoint for that patient (R2, R3, R4). Table 5 provides scales of percent frequencies of relevant 
sequences derived from stem cell (unique) or T cell (shared) data for the patient pairs selected for 
analysis. Donor-derived T cells were much higher in most analyzed VJ recombinations, so that at a 
numerical value, there were a greater overall number of T cells and a more diverse array of stem- ce
derived T cells. For example, in the first row of Table 5a, addressing Vβ 4-3 J1-1, the frequency of that 
VDJ recombination is higher in the shared population (1.7 and 1.4% of total VDJ recombinations) than
that of the unique population (0.009 and 0.004%), though these frequencies did not distinguish GVHD 
patient 9 from GVHD-free patient 3. In addition, V7-9 J2-7 had the highest frequency of unique c
whereas V-3 J1-1 had the highest frequency of shared clones in GVHD- free patient 3 which distin
this patient from GVHD patient 9 (Table 5a). However, frequency of unique or shared clones did 
show a consistent association with GVHD status. Similar observations were made comparing different
patient pairs (Table 5b-d).  
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Figure n 
with the trend of GVHD. Number of different VDJ recombination of relevant T cell clones derived 
 
(R2, R3, R4) in patient pairs 9 vs. 3 (A), 9 vs. 4 (B), 14 vs. 3 (C) and 14 vs. 4 (D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20. Distribution of donor- derived unique and shared T cell subsets fail to show correlatio
from donor stem cells (unique) or donor T cells (shared with D) at different timepoints following HSCT
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Figure 21. Relevant T cell clones associated with both GVHD and GVHD-free patients do not 
show a correlation with the ratio of unique to shared T cell subsets. Ratios of unique to shared T cell 
clones for relevant sequences were analyzed for patients 9 vs. 4 (A), 9 vs. 3 (B), 14 vs. 3 (C) and 14 vs. 
.   
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Table 5. Relevant T cell clones associated with both GVHD and GVHD-free patients do not show a
correlat
 
ion with the frequency of unique to shared T cell subsets.  Frequencies indicate the 
percentage of the most abundant VDJ sequences within all 30 TCR Vβ’s in the entirety of samples 
examined for patients 9 vs. 3 (A), 
shown 
 
 
A. 
 
highest frequency of unique 
clones 
highest frequency of shared clones 
9 vs. 4 (B), 14 vs. 4 (C) and 14 vs. 3 (D). Highest frequencies were 
 bold. in
 
 
VJ 
recombination Patient 9 Patient 3 Patient 9 Patient 3 
V4-3 J1-1 
 
0.009  0.004  1.7  1.4  
V7-9 J2-7 0.004  0.18  0.6  0.9  
V10-1 J2-1 0.03  0.035  0.2  0.07  
V14 J2-1 0. 05  0.03  0.2  1.2  
 
 
B. 
 
highest frequency of unique 
clones 
highest frequency of shared clones 
 
 
 
 
 
 
 
VJ 
recombination Patient 9 Patient 4 Patient 9 Patient 4 
V7-1 J2-1 7 x 10-4   0.09  8.2  2 x 10-5  
V7-9 J2-1  0.009  0.012  0.7  2.6  
V14 J2-1 0. 05  0.3  0.2  0.01  
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C. 
 
highest frequency of unique 
clones 
highest frequency of shared clones  
VJ 
recombination Patient 14 Patient 4 Patient 14 Patient 4 
V4-1 J2-7 0.2 0.2  0.007  0.002  
V6-1 J1-5 0.35  0.2  0.003  0.002  
V7-9 J2-1 8x 10-5  0.012  0.03  2.6  
V11- J2-1 0.004  0.025  4.5  0.008  2 
 
D. 
highest frequency of unique 
clones 
highest frequency of shared clones 
 
 
 
VJ 
recombination Patient 14 Patient 3 Patient 14 Patient 3 
V4-1 J2-7 0.2 0.0018  0.007  0.04  
V5-6 J1-1 0.004  0.6  0.25  9 X 10-4  
V7-8 J2-7 0.0025  8 x 10-4  0.1  0.02  
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GVHD- specific T s rev ssociat n frequen que T cells and 
likelihood of GVHD recovery 
ethod of analysis discussed 
clones between GVHD and GVHD-free patients, further an
that were specific to GVHD patients only. GVHD-specific clones were identified based on their skewed 
clonality in GVHD patients but not in GVHD-free patients. Figure 22 shows representative T cell clones 
based o  this crite  cl rent from those in 
en tiona erform on clone  declined at the time 
of GVHD resolution in patient 9 (Figure 23a) and persisted or increased with the persistent of GVHD in 
pa gure 2 re were fferent clon patient 9 and eight different clones in 
atient 14 which were associated with the trend of GVHD in these patients, i.e., all the clones increased 
ver the respective donors at the time of GVHD (R3) and then either decreased or persisted at R4 in 
atient 9 and patient 14, respectively (Figure 23).  
Following the selection of representative T cell clones associated with GVHD, division into T 
ell originated from donor T cells (shared T cells) and those originated from donor stem cell (unique T 
ells) subsets was conducted and the top 20 VDJ sequences from each subset were derived.  Three 
presentative clones from both GVHD patients (9 and 14) that were not shared with either GVHD- free 
atients (3 or 4) were therefore selected based on both highest counts and highest fold increase from 
onor and subjected to analysis of numbers of unique and shared T cell clone ratios (Figure 24).  Ratio 
f unique to shared T cell clones (Table 6) and frequency of unique and shared T cell clones relative to 
ll VDJ recombinations in each patient (Table 7) were then determined. In GVHD patient 9, Vβ 25-1 J1-
n 
point as shown in Figure 23a.  The same procedure was conducted for 
 cell clone ealed an a ion betwee cy of uni
In contrast to the m in the previous section that addressed shared 
alysis was conducted to uncover those clones 
n rion and shows that trends of onality in GVHD patients were diffe
GVHD-free pati ts. An addi l filtering p ed to focus s that were
tient 14 (Fi 3b). The  seven di es in 
p
o
p
c
c
re
p
d
o
a
6, Vβ 25-1 J2-2 and Vβ 27 J1-1 were selected based on both highest counts and largest decrease upo
GVHD resolution at the R4 time
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GVHD he 
able 6, upon resolution of GVHD in patient 9, the 
ratio of
ating 
ed 
 
 
 
 
 patient 14, with the difference being that increase or persistence, as opposed to decrease, of t
selected clones was critical since GVHD persisted for all timepoints in that particular patient. Based on 
these criteria, Vβ 5-4 J2-2, Vβ 5-4 J2-7, and Vβ 12-5 J2-7 were selected for a more in-depth analysis of 
GVHD- specific clones in patient 14. An outlier was Vβ 6-9 J2-2, which was not increased from donor 
at R3, but showed substantial increase at R4, indicating its potential relevance in resistance to treatment 
at R4 (Figure 18b). Vβ 5-4 J2-2, Vβ 5-4 J2-7, and Vβ 12-5 J2-7 were therefore the clones selected from 
that group which fit all three criteria of unshared status with GVHD- free patients, and increase from 
donor with persistence (or increase) throughout all timepoints.  
As shown in Figure 24, the number of unique VDJ clones was always greater than shared VDJ 
clones in both GVHD patients 9 and 14. It was uncovered that ratio of unique to shared T cells was 
associated with the trend of GVHD. As shown in T
 unique to shared T cells was reduced (Table 6a), while maintained at high levels in patient 14, 
whose GVHD persisted until death (Table 6b). As an example, for Vβ 25 J1-6 in Table 6a, which 
depicts the ratios for patient 9  between timepoint R3, and timepoint R4, all are reduced at R4, indic
a reduction in stem-cell derived T cells at that timepoint, since the number of shared T cell clones is 
zero. Patient 14, on the other hand, had persistent GVHD, and their stem cell – to- T cell ratio increas
as GVHD progressed (from R3 to R4), which is indicated on Table 6b. The only exception in patient 14
was Vβ6-9 J2-2 that did not maintain high ratio of unique to shared T cells at R4 compared to R3 (Table
6b), because this clone emerged at R4 and it was absent at R3 (Figure 23b). This may suggest that 
emergence of new clones at R4 in addition to the persistence of GVHD-associated clones at R3 and R4
may cause resistance to therapy for GVHD in patient 14.  
However, numbers of unique or shared T cell clones indicates their diversity rather than their 
direct involvement in GVHD reactivity. To determine whether unique or shared T cells may be involved
75 
 
in GVHD, frequency or abundance of these clones were determined in patients 9 and 14. As shown in 
Table 7a, frequency of all three shared clones (second and third columns) was smaller than unique 
clones (fourth and fifth columns) in patient 9 who responded to treatment and resolved GVHD at R4. In 
addition, frequency of such unique clones that emerged at R4 was also smaller than those at R3 (fourth 
and fifth columns, Table 7a). On the other hand, patient 14 who showed persistent GVHD had higher 
frequency of shared T cell clones (second and third column, Table 7b) than unique clones (fourth and 
fifth co
tion, 
s 
 
o 
 
 
lumns, Table 7b). In addition, number of new T cell clones emerged at R4 remained high 
compared to shared clones that were only present at R3 (fourth and fifth columns, Table 7b). In addi
frequency of unique clones decreased at R4, when GVHD was resolved in patient 9 (Table 7a) wherea
both shared and unique T cell clones increased with the persistence of GVHD at R4 in patient 14 (Table
7b). Clones that were unique and shared between donor and recipient at both R3 and R4 were also 
analyzed. It was found that clones at both timepoints in patient 9 follow a similar trend in that the 
frequency of clones decreases at R4 when GVHD resolves (Table 7c). On the other hand, there was n
discernible trend in those clones at both timepoints for patient 14, in which some frequencies increased, 
some decreased and some remained the same from R3 to R4 (Table 7d). These data suggest that 
although both unique and shared T cells may be involved in GVHD, persistence of GVHD in patient 14 
may be determined by high frequency of shared T cells whereas high frequency of unique T cell clones 
may predict a good prognosis for GVHD therapy.  
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Figure 22. GVHD- specific TCR Vβ’s show distinct clonality compared to GVHD-free patients. 
and 3 for Vβ 25 J1-6 & Vβ 25 J2-2 (A) or Vβ 27 J1-1 (B), and in patients 14 vs. 4 and 3 for Vβ 5-4 J2-2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GVHD-specific clones were identified by comparative analysis of VJ recombinations in patients 9 vs. 4 
 
& Vβ 5-4 J2-7 (C) or Vβ 12-5 J2-7 (D).  
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Figure 23. Certain GVHD- specific VJ recombinations are associated with the trend of GVHD. 
Fold increases of relevant GVHD-specific T cell clones over the respective donors at R3 and R4 
timepoints were analyzed for GVHD patient 9 (A) and patient 14 (B).  
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Figure Distribution of donor-derived unique and shared T cell subsets show a correlation with 
the trend of GVHD.  Number of different VDJ recombinations of relevant T cell clones derived from 
donor stem cells (unique) or donor T cells (shared with D) at different timepoints following HSCT (R2, 
R3, R4) in GVHD patients 9 and 14.  
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Table 
resolution and increased during GVHD progression. Ratios of unique to shared T cell clones for 
relevant VDJ sequences were analyzed for GVHD patient 9 (A) and patient 14 (B). 
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Table 7.  The frequency of unique and shared GVHD-specific T cell clones is decreased upon 
ogression. Scale of frequencies indicate the 
percentage of the m  un re VDJ sequences that were present at R3 or R4 
timepoints for patient 9 (A) and patient 14 (B) or were present at both R3 and R4 timepoints for patient 
9 14
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Discussion 
 
We performed a pilot study in patients with hematologic malignancies who received allogeneic 
ste plantati rder to ine th e
atients were selected among 13 patients (5 GVHD-free and 8 with GVHD, Table 1) representing mild 
VHD that was resolved following treatment (patient 9, Table 2); severe GVHD that was resistant to 
erapy (patient 14, Table 2) as well as two patients with full donor T cell chimerism (patient 3, Table 3) 
r mixed donor T cell chimerism (patient 4, Table 3) who remained GVHD-free and relapse-free over 
ne year after HSCT. We showed that skewed clonality and usage frequency of TCR VβJ compared to 
espective donors can indicate tissue- reactivity of T cells that cause either GVHD or result in GVHD-
free survival, perhaps as a result of natio al tu  Ou  data also suggest that 
are mbinations between with 
free, there are differences between the DJ recombin olecular 
level that distinguish them from one another. Finally, the ratio and frequency of unique to shared T cells 
th iated h GVH VHD vival f demonstrate a discernible 
difference between the two patient subsets. In contrast, such ratio and frequency patterns predicted 
disease outcome when GVHD-specific clones that were unshared with GVHD-free patients were 
analyzed. In fact, the ratio of unique to shared T cell clones that increased over their respective donors at 
GVHD onset persisted or decreased as GVHD progressed or resolved, respectively. In addition, high 
frequencies of donor-derived T cells (shared T cell clones) in GVHD patients were associated with 
disease outcome, suggesting that while ratio of unique to shared T cell clones may predict the trend of 
the disease, frequency of the shared T cell subset may be a critical component in predicting severity of 
disease in addition to responsiveness to treatment. In brief, analysis of shared and unique T cell clones 
m cell trans on in o  determ e molecular basis of T cell-m diated GVHD. Four 
p
G
th
o
o
r
 the elimi n of residu
 patients 
mor cells.
GVHD and patients that are GVHD-
r
despite certain sh d VJ reco
 V ations in the two subsets of patients at a m
at were assoc with bot D and G -free sur ailed to 
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suggest that while both T cell and stem cell components of transplant are involved in GVHD reactivity, 
high fr
xt 
have 
 of 
cell 
h 
equency of the T cell component is associated with poor prognosis whereas high frequency of 
stem cell component may predict good prognosis for the treatment of GVHD. 
The benefit of isolation of T cell mRNA (as opposed to DNA) in our analyses is that it gives a 
snapshot of what proteins may be translated in the recipient and donor microenvironment. In this conte
it is exposing those T cell clones that may be active at the various timepoints during the GVHD disease 
progression. The selective proliferation of T cells is a result of antigen-specific induction, and during a 
graft-versus-host response with no other co-morbidities, it can be reasonably assumed that the antigen 
that is inducing the expansion of a particular VDJ recombination is host tumor tissue.18 From this 
induction, those T cell clones that are experiencing specific clonal expansion provide critical 
information about particular VDJ recombinations in T cells indicative of disease.  
Of the four patients analyzed, all but one (patient 4) had nearly full donor T cell chimerism at all 
timepoints. Patterns of clonality are altered significantly from R2 to R3 in many of the selected clones in 
patient 4. Changes in the pattern of clonality in patient 4 from the R2 timepoint to the R3 timepoint 
the potential to be indicative of the mixed chimerism at the R2 timepoint. The observation that none
the eight GVHD patients studied as opposed to 4 out of 5 of the GVHD-free patients had donor T 
chimerism of above 10% at any time (Table 3) supports observations that mixed chimerism is critical for 
tolerance induction.45  Self- tolerance, while decreasing the likelihood of GVHD, may also reduce 
GVT.46 However, expression of tumor-specific mHA can result in GVT effects without GVHD, as 
shown in this study. In addition, mixed chimeras have been found to produce less effector T cells, whic
could be demonstrated in the observation that 4 of the 5 patients who were GVHD-free had mixed 
chimerism at some point.46  
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TCR Vβ’s that are shared between patients with GVHD and GVHD-free survival differ from on
another at a molecular (VDJ sequence) level 
e 
Ou
s 
 from 
ken into 
 between the two 
gro  
 
 
2). 
L, and neither relapsed from their disease following treatment, which 
ould indicate that this shared sequence may be specific to tumor. This single shared sequence out of 
many top sequences coincides with evidence that dictates that while there are many antigens that have 
r first hypothesis that clones of which their expression is upregulated in recipients compared to 
donor in both subsets of patients (GVHD and GVHD- free), the TCR Vβ will differ at a molecular level 
between the two subsets due to differences in mHAs was supported by molecular analysis of VDJ 
recombinations of TCR Vβ. The select VJ recombinations chosen based on shared clonality patterns 
between GVHD and GVHD-free patients were examined on a molecular level of the top VDJ sequence
of relevant clones expressed in the given VJ recombination. Those engrafted and expanded T cells
donor have already completed development, and only variances in the D region, which was ta
account in the molecular analysis of VDJ sequences, can account for the variability
ups. On the other hand, since newly formed T cells develop in the recipient microenvironment from
donor stem cells, they have an additional level of complexity that can allow for differences in the CDR3 
region. During the development and subsequent recombination of the V, D, and J regions, these T cells 
also acquire random nucleotide insertions at each junction point, leading to another layer of diversity in 
this T cell subset. 
One of the primary complications of attempts to eradicate tumors using immune system cells is that 
many antigens that are expressed on tumors are also shared ubiquitously with healthy host tissue.8 From
all of the uncovered high-frequency relevant sequences within each shared (originated from donor T
cells) and unique (originated form donor stem cells) subsets, one sequence was found that was shared (a 
donor-derived sequence in V4-3 J1-1) between GVHD patient 9 and GVHD-free patient 3 (Figure 1
Both patients 9 and 3 had NH
c
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the potential to be recognized during GVHD and GVT, a select few of those antigens are expressed 
solely on tumor. Distinct molecular signatures (VDJ recombinations) of certain TCR Vβ that were 
ass
ns 
Bo
f 
 
ociated with both GVHD and GVHD-free survival also suggest distinct antigenic profiles between 
tumor cells and self cells. Therefore, this VDJ sequence shared between two patients with the same 
disease who recovered from said disease following treatment could express tumor associated antige
(TAAs) and a TCR specific to that antigen following HSCT.8   
The diversity of polymorphisms in the entirety of the human population would lead to the reasonable 
assumption that there is a nearly endless supply of host antigens that can initiate a response in donor T 
cells. This fact coincides with the observation that there was great diversity in Vβ families that were 
clonal in GVHD patients, as GVHD induces the proliferation of specific T cells and our observations 
that there were few shared VDJ sequences between GVHD and GVHD-free patients.11 Therefore, the 
observation that few shared clones existed between patients supports data that confirm the ubiquitous 
expression of a variety of polymorphic mHA’s capable of initiating a response in donor T cells upon 
engraftment.  
 
th ratio and frequency of GVHD-specific shared and unique T cells provide information about 
progression and severity of GVHD 
Our second hypothesis that both T cells and stem cells are involved in GVHD such that severity o
GVHD is determined by T cell rather than stem cell component of transplant is supported by our data 
showing that the ratio of unique to shared T cells was associated with trend of GVHD such that this ratio
dropped upon GVHD resolution and remained unchanged or increased when GVHD persisted. 
Importantly, it was the frequency of shared T cells that were expanded from T cell component of 
transplant that predicted poor prognosis for the treatment of GVHD. In fact, patient 9, whose GVHD 
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was resolved, showed higher frequency of unique T cells whereas patient 14 whose GVHD persisted
showed higher frequency of shared T cells (Table 7).  
Donor T cells undergo selection in the donor microenvironment and upon exposure to host tissue 
following engraftment, donor T cells recognize it as foreign since positive and negative selections ha
already occurred outside of the host microenvironment.5 In contrast, donor stem cells can undergo 
positive and negative selections in the recipient's microenvironm
 
ve 
ent and generate unique mature T cells 
that
 
should be almost entirely from peripheral expansion.24 How are new T cells being 
enerated? Studies demonstrate that by the age of 60, the ability of the thymus to regenerate T cells from 
 was 59, and the average age of GVHD-free patients was 54. The 
ave o 
bution 
 of 
 
 were absent in the donor. Such T cell maturation can take place in the extrathymic niche in adults. 
31,35 Therefore, high affinity tissue- reactive unique clones may be eliminated, leaving those that still 
have the potential for weak reactivity. This would explain the observation that severity of disease is 
correlated with the T cell rather than the stem cell- derived population.  
A query that arises from these conclusions stems from the observation that in older adults, such as 
those in this study, the thymus should be quite atrophied, with very limited potential for T cell renewal
from naïve T cells.21,22 This begs the question that if the thymus should be mostly inactive, T cell 
replenishment 
g
stem cells is minimal in patients undergoing non-myoablative conditioning for HSCT.21,26  The average 
age of the GVHD patients in our study
rage age of the two studied GVHD patients (patients 9 and 14) was 56 and the average age of the tw
studied GVHD free patients (3 and 4) was a mere 45. Within the age limitations of our study, the 
thymuses of these patients may still be capable of reconstituting immune cells following transplant.21,26 
Secondly, hematopoietic peripheral expansion (HPE) makes a larger and more significant contri
to immune reconstitution in the thymectomized host than in euthymic host, meaning that in a state
thymic damage, the likelihood of extrathymic ability to recover T cell population actually increases.21
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Extrathymic selection has been observed in the small intestine and lymph nodes of thymectomized mi
as well as in the tonsil of adult humans, and is a potent
ce, 
ial additional route of selection in GVHD patients 
wit  
R3 
tant to treatment (those whose 
freq
 
 
e 
 This 
f 
h atrophied thymuses.2,31,36,38,39. These data support the potential for extrathymic selection to be an
alternative source of T cells for patients with reduced thymic capacity, as in those undergoing 
HSCT.31,38  
In patient 14, who had progressive GVHD until death, unique newly emerging clones could 
contribute to severity of GVHD. Emergence of new clones may explain resistance to treatment, and is 
demonstrated by fluctuations in frequencies of GVHD-specific VDJ sequences that are found at both 
and R4 (Table 7). Those combinations that were reduced in frequency could represent a response to 
treatment, leaving room for the expansion of those clones that were resis
uencies increased as GHVD progressed). Ratio of unique to shared T cell clones was always 
associated with the trend of GVHD. The only outlier in GVHD patient 14, V6-9 J2-2, that did not follow
such a trend suggest the emergence of new clones that are resistant to treatment. Clones for this VJ
recombination showed very low overall frequencies at R3 (5-2 total clones were detected within th
entire Vβ repertoire for individual VDJ sequences) while the frequencies for the single VDJ clone that 
emerged at R4 were substantially higher, approximately a 42-fold increase from the highest clones in 
either donor or R3, attributes to its relevance.  
In general, the number of unique clones was higher than that of shared T cells. In contrast, the 
overall frequency of shared T cell clones within the entire Vβ population for a patient was greater.
was an overarching theme in both GVHD and GVHD-free patients. Higher overall frequencies from the 
T cell versus the stem cell subset confirm the observation that although stem cells produce a more 
diverse array of sequences, their tissue- associated proliferation rates are consistently lower than their 
donor- derived T cell counterparts. This is consistent with data that indicate that thymic reconstitution o
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T cells results in a polyclonal, diverse array of T cells following a lymphodepletive treatment that 
substantially reduces T cell diversity.5,25  
How can the unique subset be readily defined as from donor- derived stem cells? At most of the 
timepoints studied (R3 for patient 4, R2 for patient 3, R3 and R4 for patient 14 and R3 and R4 
patient 9) do
for 
nor T cell chimerism was not 100%. In a healthy environment, T cell reconstitution from 
stem nes 
 
e 
hat 
eration.11,12,21 The observation that there are a greater 
num  
 
 cells should result in a Gaussian distribution in a spectratype, which none of the relevant clo
considered for analysis had. 21 However, a skewed spectratype would be expected in patients during an
antigen- specific response. Since the GVHD- free patients in this study did not relapse, it can be 
assumed that GVT was occurring. Therefore, all 13 patients were either experiencing clinical 
manifestation of GVHD or GVT, and in fact were all experiencing an antigen- driven response of some 
kind. This lends to the fact that regardless of incomplete chimerism, the stem cell subset can still b
donor derived and demonstrate a skewed spectratype graph. Another important conclusion is that 
transplant regimens reduce host naïve T cell populations by about 95%, making it even more likely t
unique T cells are donor derived as opposed to latent recipient cells.25 
The high diversity of unique clones is supported by studies that indicate that generation of novel 
VDJ recombinations tends to result in a diverse and polyclonal repertoire of T cells due to the random 
nucleotide insertions associated with T cell gen
ber of different unique clones contributing to GVHD coincides with the fact that there will be a
more diverse population due to the high number of various polymorphic antigens that are presented to 
the emerging T cells upon engraftment into host. This results in a high number of recipient antigens 
recognized by donor stem cells, as opposed to the smaller number of different TAAs recognized by
donor cells. 8 In addition, since there are few tumor- specific antigens within the large population of 
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potential mHAs within the host, the observation that a diverse group of TCR Vβ’s would be involv
GVHD, and much less diverse in GVT is justif
ed in 
ied.39  
n to 
er 
s well.5 
 terms of 
J 
ared 
lecular analysis of TCR Vβ in 
larg
 
 
further validate our findings by analyzing five GVHD-free and eight GVHD patients that were included 
Since a patient undergoing HSCT has been pre-treated with anti-thymocyte antibodies, they will 
have a diminished or entirely depleted T cell population, leaving ample room for a donor populatio
expand.6,11 This is designed so that those clones that are engrafted into host will receive a substantial 
proportion of proliferative cytokines and be the most likely to expand. Therefore, the higher the numb
of a VDJ recombination, the larger its population will be following engraftment. In addition, those 
clones that recognize antigen will also consume homeostatic proliferative cytokines and expand a
Since shared sequences are those that engraft into recipient, they already have an advantage in
proliferation and completion for cytokines over newly developing T cells from donor cells and 
proliferation will happen more readily and to a greater degree initially upon engraftment in those VD
recombinations that have already been established. This “head start” will make actual counts of sh
sequences higher, even though the unique sequences are more diverse. 
In conclusion, our finding through this pilot study can guide mo
e cohorts of patients in order to determine molecular features of GVHD and GVT following 
allogeneic HSCT. These data suggest that allogeneic HSCT may be improved by optimizing the proportion
of T cells to stem cells in the transplant as well as developing targeted therapy against GVHD-associated T
cell clones while rescuing GVT-associated T cell clones. 
 
Future directions 
An algorithm needs to be developed by application of the proposed analysis to a larger cohort of 
patients in order to predict prognosis of allogeneic HSCT. We are to develop a statistical model to 
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in this study. Further research could also optimize T cell to stem cell ratio in the transplant in order to 
achieve GVT effects without GVHD complications. Molecular targeted therapy for GVHD should also 
be i
 
 
nvestigated based on the identification of GVHD-associated VDJ recombinations.  
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